PROOF
25 Nov 2020
PROOF
NCT03773302
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial
QED Therapeutics
Cancer Type | Other |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | Cholangiocarcinoma |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2019-12-27 |
Anticipated End Date | 2026-12-30 |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Dr Nimit Singhal |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs